Antibodies having altered effector function and methods for making the same

• US 7,863,419 B2
• Filed: 02/22/2006
• Issued: 01/04/2011
• Est. Priority Date: 08/22/2003
• Status: Active Grant

• Current Assignee: Biogen MA Inc. (Biogen, Inc.)
• Original Assignee: Biogen Idec MA Inc. (Biogen, Inc.)
• Inventors: Taylor, Frederick R., Garber, Ellen
• Primary Examiner(s): OUSPENSKI, ILIA I
• Application Number:
  US11/360,938
• Publication Number:
  US 20070048300A1
• Time in Patent Office: 1,777 Days
• Field of Search: None
• US Class Current: 530/350
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/2875 against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 against NGF C07K16/22, against TNF C07K16/241
• CPC Class Codes: C07K 2317/21 : from primates, e.g. man
• CPC Class Codes: C07K 2317/41 : Glycosylation, sialylation, or fucosylation
• CPC Class Codes: C07K 2317/52 : Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/71 : Decreased effector function due to an Fc-modification

Abstract

The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.

Claims

1. A variant polypeptide of a parent polypeptide comprising an Fc region, wherein the Fc region of the variant polypeptide comprises a modified first amino acid residue at T299 of the Fc region according to the Kabat numbering system of IgG immunoglobulins, the modified first amino acid residue having a side chain chemistry selected from the group consisting of a side chain chemistry comprising a cysteine thiol, a side chain chemistry of sufficient steric bulk such that the polypeptide displays reduced effector function, and a side chain chemistry of sufficient electrostatic charge such that the polypeptide displays reduced effector function, and a second amino acid residue at N297 of the Fc region according to the Kabat numbering system of IgG immunoglobulins, the second amino acid having reduced glycosylation, wherein the variant polypeptide has reduced effector function as compared to the parent polypeptide.

2. The variant polypeptide of claim 1, wherein the side chain chemistry of the modified first amino acid residue comprises a cysteine thiol.

3. The variant polypeptide of claim 1, wherein the side chain chemistry is of sufficient steric bulk such that the polypeptide displays reduced effector function.

4. The variant polypeptide of claim 3, wherein the side chain chemistry of sufficient steric bulk is that of an amino acid residue selected from the group consisting of Phe, Trp, His, Glu, Gln, Arg, Lys, Met, and Tyr.

5. The variant polypeptide of claim 1, wherein the side chain chemistry is of sufficient electrostatic charge such that the variant polypeptide displays reduced effector function.

6. The variant polypeptide of claim 5, wherein the side chain chemistry is that of an amino acid residue selected from the group consisting of Asp, Glu, Lys, Arg, and His.

7. The variant polypeptide of claim 1, wherein the reduced effector function is reduced binding to an Fc receptor (FcR).

8. The variant polypeptide of claim 7, wherein the binding is reduced by a factor selected from the group consisting of about 1-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 15-fold, about 50-fold, and about 100-fold.

9. The variant polypeptide of claim 7, wherein the Fc receptor (FcR) is selected from the group consisting of Fcγ

RI, Fcγ

RII, and Fcγ

RIII.

13. The polypeptide of claim 1, wherein the first amino acid residue is modified by substitution by a replacement amino acid.

14. The variant polypeptide of claim 13, wherein the replacement amino acid is a non-traditional amino acid residue.

15. The variant polypeptide of claim 1, wherein the first amino acid residue is capable of being linked to a functional moiety.

16. The variant polypeptide of claim 15, wherein the functional moiety is selected from the group consisting of a blocking moiety, a detectable moiety, a diagnostic moiety, and a therapeutic moiety.

17. The variant polypeptide of claim 16, wherein the blocking moiety is selected from the group consisting of a cysteine adduct, mixed disulfide, polyethylene glycol, and polyethylene glycol maleimide.

18. The variant polypeptide of claim 16, wherein the detectable moiety is selected from the group consisting of a fluorescent moiety and isotopic moiety.

19. The variant polypeptide of claim 16, wherein the diagnostic agent is capable of revealing the presence of a disease or disorder.

20. The variant polypeptide of claim 16, wherein the therapeutic moiety is selected from the group consisting of an anti-inflammatory agent, an anticancer agent, an anti-neurodegenerative agent, and an anti-infective agent.

23. The variant polypeptide of claim 1, wherein the polypeptide is pegylated at the modified first amino acid residue.

24. The variant polypeptide of claim 2, wherein the polypeptide is pegylated with PEG-maleimide.

25. The variant polypeptide of claim 1, wherein the modified first amino acid residue is a cysteine residue modified by a cysteine or mixed disulfide adduct.

26. The variant polypeptide of claim 1, wherein the polypeptide is an antibody variant.

27. The variant polypeptide of claim 1, wherein the Fc region is obtained from an antibody of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

28. The variant polypeptide of claim 1, wherein the polypeptide binds to an antigen selected from the group consisting of a ligand, cytokine, receptor, cell surface antigen, and cancer cell antigen.

10. The variant polypeptide of 1, wherein the reduced effector function is reduced binding to a complement protein.

11. The variant polypeptide of claim 10, wherein the complement protein is C1q.

12. The variant polypeptide of claim 10, wherein the reduced binding to a complement protein is by a factor selected from the group consisting of about 1-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, and about 15-fold.

21. A variant polypeptide of a parent polypeptide comprising an IgG1 Fc region, wherein the Fc region of the variant polypeptide comprises an amino acid at position 299 which differs from the amino acid at position 299 of the parent polypeptide, wherein the amino acid at position 299 of the parent polypeptide is threonine and the amino acid at position 299 of the variant polypeptide is selected from the group consisting of alanine, asparagine, glycine, tyrosine, cysteine, histidine, glutamic acid, aspartic acid, lysine, arginine, isolucine, leucine, methionine, phenylalanine, proline, tryptophan, and valine, and wherein the variant polypeptide comprises an amino acid at position 297 of the Fc region having reduced glycosylation and displays reduced effector function as compared to the parent polypeptide.

22. The variant polypeptide of claim 21, wherein the amino acid at position 299 is a cysteine.

29. The polypeptide of claim 21, wherein the amino acid at position 299 is an alanine.

30. A composition comprising the variant polypeptide of claim 29 in a suitable pharmaceutical carrier.

71. The variant polypeptide of claim 21, wherein the amino acid at position 299 is asparagine.

72. The variant polypeptide of claim 21, wherein the amino acid at position 299 is glycine.

73. The variant polypeptide of claim 21, wherein the amino acid at position 299 is tyrosine.

74. The variant polypeptide of claim 21, wherein the amino acid at position 299 is histadine.

75. The variant polypeptide of claim 21, wherein the amino acid at position 299 is glutamic acid.

76. The variant polypeptide of claim 21, wherein the amino acid at position 299 is aspartic acid.

77. The variant polypeptide of claim 21, wherein the amino acid at position 299 is a lysine.

78. The variant polypeptide of claim 21, wherein the amino acid at position 299 is an arginine.

79. The variant polypeptide of claim 21, wherein the amino acid at position 299 is isoleucine.

80. The variant polypeptide of claim 21, wherein the amino acid at position 299 is leucine.

81. The variant polypeptide of claim 21, wherein the amino acid at position 299 is methionine.

82. The variant polypeptide of claim 21, wherein the amino acid at position 299 is phenylalanine.

83. The variant polypeptide of claim 21, wherein the amino acid at position 299 is proline.

84. The variant polypeptide of claim 21, wherein the amino acid at position 299 is tryptophan.

85. The variant polypeptide of claim 21, wherein the amino acid at position 299 is valine.

31. An antibody variant of a parent antibody, wherein the antibody variant comprises an Fc region comprising a replacement amino acid substituted for the threonine at position 299 of the Fc region according to the Kabat numbering system for IgG immunoglobulins, the substituted amino acid residue having a side chain chemistry selected from the group consisting of a side chain chemistry comprising a cysteine thiol, a side chain chemistry of sufficient steric bulk such that the polypeptide displays reduced effector function, and a side chain chemistry of sufficient electrostatic charge such that the polypeptide displays reduced effector function and a second amino acid residue at N297 of the Fc region according to the Kabat numbering system for IgG immunoglobulins, the second amino acid residue having reduced glycosylation as compared to the parent antibody.

32. The antibody variant of claim 31, which has reduced effector function.

34. The antibody variant of claim 31, wherein the Fc region is from an IgG1 antibody.

37. The antibody variant of claim 31, wherein the Fc region is from an IgG4 antibody.

38. The antibody variant of claim 37, wherein the replacement amino acid at position 299 is a cysteine.

39. The antibody variant of claim 37, wherein the Fc region further comprises an amino acid at position 228 which differs from the amino acid at position 228 of the parent antibody, wherein the amino acid at position 228 of the parent antibody is a serine and the amino acid at position 228 of the variant antibody is a proline.

40. The antibody variant of claim 37, wherein the amino acid at position 299 is alanine.

42. The antibody variant of claim 37, wherein the amino acid at position 299 is asparagine.

44. The antibody variant of claim 37, wherein the amino acid at position 299 is glycine.

46. The antibody variant of claim 37, wherein the amino acid at position 299 is tyrosine.

48. The antibody variant of claim 37, wherein the amino acid at position 299 is histadine.

50. The antibody variant of claim 37, wherein the amino acid at position 299 is glutamic acid.

52. The antibody variant of claim 37, wherein the amino acid at position 299 is aspartic acid.

54. The antibody variant of claim 37, wherein the amino acid at position 299 is lysine.

56. The antibody variant of claim 37, wherein the amino acid at position 299 is arginine.

58. The antibody variant of claim 37, wherein the the amino acid at position 299 is isoleucine.

60. The antibody variant of claim 37, wherein the amino acid at position 299 is leucine.

62. The antibody variant of claim 37, wherein the amino acid at position 299 is methionine.

64. The antibody variant of claim 37, wherein the amino acid at position 299 is phenylalanine.

66. The antibody variant of claim 37, wherein the amino acid at position 299 is proline.

68. The antibody variant of claim 37, wherein the amino acid at position 299 is tryptophan.

70. The antibody variant of claim 37, wherein the amino acid at position 299 is valine.

33. A varaint antibody of a parent antibody comprising an IgG1 Fc region, wherein the Fc region of the variant antibody comprises an amino acid at position 299 which differs from the amino acid at position 299 of the parent antibody, wherein the amino acid threonine at position 299 of the parent antibody is threonine and the amino acid at position 299 of the variant antibody is selected from the group consisting of alanine, asparagine, glycine, tyrosine, cysteine, histidine, glutamic acid, aspartic acid, lysine, arginine, isolucine, leucine, methionine, phenylalanine, proline, tryptophan, and valine, and wherein the variant antibody comprises an amino acid at position 297 of the Fc region having reduced glycosylation and displays reduced effector function as compared to the parent polypeptide.

35. The antibody variant of claim 33, wherein the replacement amino acid residue at position 299 is an alanine.

36. The antibody variant of claim 33, wherein the replacement amino acid residue at position 299 is a cysteine.

41. The antibody variant of claim 33, wherein the amino acid at position 299 is asparagine.

43. The antibody variant of claim 33, wherein the amino acid at position 299 is glycine.

45. The antibody variant of claim 33, wherein the amino acid at position 299 is tyrosine.

47. The antibody variant of claim 33, wherein the amino acid at position 299 is histadine.

49. The antibody variant of claim 33, wherein the amino acid at position 299 is glutamic acid.

51. The antibody variant of claim 33, wherein the amino acid at position 299 is aspartic acid.

53. The antibody variant of claim 33, wherein the amino acid at position 299 is lysine.

55. The antibody variant of claim 33, wherein the amino acid at position 299 is arginine.

57. The antibody variant of claim 33, wherein the amino acid at position 299 is isoleucine.

59. The antibody variant of claim 33, wherein the amino acid at position 299 is leucine.

61. The antibody variant of claim 33, wherein the amino acid at position 299 is methionine.

63. The antibody variant of claim 33, wherein the amino acid at position 299 is phenylalanine.

65. The antibody variant of claim 33, the amino acid at position 299 is proline.

67. The antibody variant of claim 33, wherein the amino acid at position 299 is tryptophan.

69. The antibody variant of claim 33, wherein the amino acid at position 299 is valine.

86. A composition comprising the antibody variant of claim 35 in a suitable pharmaceutical carrier.

87. A variant polypeptide of a parent polypeptide comprising an IgG 1 Fc region, wherein the Fc region of the variant polypeptide comprises an amino acid at position 299 which differs from the amino acid at position 299 of the parent polypeptide, wherein the amino acid at position 299 of the parent polypeptide is threonine and the amino acid at position 299 of the variant polypeptide is an alanine, and wherein the variant polypeptide comprises an amino acid at position 297 of the Fc region having reduced glycosylation and displays reduced effector function as compared to the parent polypeptide.

88. A variant polypeptide of a parent polypeptide comprising an IgG4 Fc region, wherein the Fc region of the variant polypeptide comprises an amino acid at position 299 which differs from the amino acid at position 299 of the parent polypeptide, wherein the amino acid at position 299 of the parent polypeptide is threonine and the amino acid at position 299 of the variant polypeptide is an alanine, and wherein the variant polypeptide comprises an amino acid at position 297 of the Fc region having reduced glycosylation and displays reduced effector function as compared to the parent polypeptide.